Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.22 USD | -0.12% | -1.24% | +70.02% |
Apr. 30 | North American Morning Briefing : More Earnings -2- | DJ |
Apr. 29 | Ladenburg Thalmann Downgrades Acrivon Therapeutics to Neutral | MT |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 1.01M | Capitalization | 254M |
---|---|---|---|---|---|
Net income 2024 * | -84M | Net income 2025 * | -103M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 252 x |
P/E ratio 2024 * |
-2.91
x | P/E ratio 2025 * |
-2.84
x | Employees | 60 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.08% |
1 day | -9.46% | ||
1 week | -13.37% | ||
Current month | -9.46% | ||
1 month | +13.52% | ||
3 months | +113.21% | ||
6 months | +62.01% | ||
Current year | +67.28% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 18-03-31 | |
Kristina Masson
FOU | Founder | 44 | 18-02-28 |
Director of Finance/CFO | 53 | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 55 | Feb. 07 | |
Sharon Shacham
BRD | Director/Board Member | 53 | 20-09-30 |
Chief Executive Officer | 62 | 18-03-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +1.32% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 8.365 | +1.64% | 6 870 |
24-05-01 | 8.23 | -9.46% | 259,236 |
24-04-30 | 9.09 | -9.10% | 130,151 |
24-04-29 | 10 | +18.20% | 239,780 |
24-04-26 | 8.46 | -0.12% | 276,495 |
Delayed Quote Nasdaq, May 01, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.28% | 254M | |
+0.67% | 42.4B | |
+44.30% | 40.04B | |
-6.20% | 28.31B | |
+6.55% | 24.94B | |
-21.66% | 18.96B | |
+29.96% | 12.3B | |
-1.57% | 11.95B | |
+16.03% | 11.32B | |
-4.80% | 11.55B |
- Stock Market
- Equities
- ACRV Stock